Effect of Statins on Renal Function in Chronic Kidney Disease Patients

Ping Jen Hu, Mei Yi Wu, Tsu Chen Lin, Tzu Ting Chen, Yun Chun Wu, Sui Lung Su, Kuo Cheng Lu, Jin Shuen Chen, Fung Chang Sung, Chien Te Lee, Yu Yang, Shang Jyh Hwang, Ming Cheng Wang, Yung Ho Hsu, Hung Yi Chiou, Chung Shun Wong, Yuh Feng Lin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Dyslipidemia is associated with glomerular injury. However, the effect of statins on chronic kidney disease (CKD) progression remains controversial. We aimed to investigate the efficacy of statins for renal protection in patients with CKD. The retrospective cohort study comprised 3441 patients diagnosed with CKD in multiple medical centers. We divided the patients into two cohorts based on statin prescription, and compared proportions and risks of CKD progression events between the two groups. CKD progression event was defined as an average annual decline of eGFR >5 mL/min/1.73 m2 or advancement to the dialysis stage. The result revealed that among all incident patients with CKD, 28.7% and 30.3% of the users and nonusers demonstrated CKD progression, respectively. The crude odds ratio (OR) of CKD progression was 0.93 [95% confidence interval (CI) 0.78–1.10]. After adjustment for baseline characteristics, the adjusted OR was 0.80 (95% CI 0.63–1.01). The sensitivity analysis results showed consistent OR for CKD progression, stratification by age, sex, Charlson score, and statins use within 1 year before index date. The effect of statins was significant in patients with CKD stage 3B-5 (OR 0.68, 95% CI 0.48–0.95), but not statistically significant in those with CKD stage 1–3A (OR 0.97, 95% CI 0.68–1.38). The effect of statins was significant in patients with proteinuria ≥1000 mg/day (OR 0.63, 95% CI 0.43–0.92), but not statistically significant in those with proteinuria <1000 mg/day (OR 1.02, 95% CI 0.74–1.41).

Original languageEnglish
Article number16276
JournalScientific Reports
Volume8
Issue number1
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Chronic Renal Insufficiency
Kidney
Disease Progression
Odds Ratio
Confidence Intervals
Proteinuria
Dyslipidemias
Prescriptions
Dialysis
Cohort Studies
Retrospective Studies

ASJC Scopus subject areas

  • General

Cite this

Effect of Statins on Renal Function in Chronic Kidney Disease Patients. / Hu, Ping Jen; Wu, Mei Yi; Lin, Tsu Chen; Chen, Tzu Ting; Wu, Yun Chun; Su, Sui Lung; Lu, Kuo Cheng; Chen, Jin Shuen; Sung, Fung Chang; Lee, Chien Te; Yang, Yu; Hwang, Shang Jyh; Wang, Ming Cheng; Hsu, Yung Ho; Chiou, Hung Yi; Wong, Chung Shun; Lin, Yuh Feng.

In: Scientific Reports, Vol. 8, No. 1, 16276, 01.12.2018.

Research output: Contribution to journalArticle

Hu, PJ, Wu, MY, Lin, TC, Chen, TT, Wu, YC, Su, SL, Lu, KC, Chen, JS, Sung, FC, Lee, CT, Yang, Y, Hwang, SJ, Wang, MC, Hsu, YH, Chiou, HY, Wong, CS & Lin, YF 2018, 'Effect of Statins on Renal Function in Chronic Kidney Disease Patients', Scientific Reports, vol. 8, no. 1, 16276. https://doi.org/10.1038/s41598-018-34632-z
Hu, Ping Jen ; Wu, Mei Yi ; Lin, Tsu Chen ; Chen, Tzu Ting ; Wu, Yun Chun ; Su, Sui Lung ; Lu, Kuo Cheng ; Chen, Jin Shuen ; Sung, Fung Chang ; Lee, Chien Te ; Yang, Yu ; Hwang, Shang Jyh ; Wang, Ming Cheng ; Hsu, Yung Ho ; Chiou, Hung Yi ; Wong, Chung Shun ; Lin, Yuh Feng. / Effect of Statins on Renal Function in Chronic Kidney Disease Patients. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
@article{768eca52572a48a7afb4016ccf9f61ce,
title = "Effect of Statins on Renal Function in Chronic Kidney Disease Patients",
abstract = "Dyslipidemia is associated with glomerular injury. However, the effect of statins on chronic kidney disease (CKD) progression remains controversial. We aimed to investigate the efficacy of statins for renal protection in patients with CKD. The retrospective cohort study comprised 3441 patients diagnosed with CKD in multiple medical centers. We divided the patients into two cohorts based on statin prescription, and compared proportions and risks of CKD progression events between the two groups. CKD progression event was defined as an average annual decline of eGFR >5 mL/min/1.73 m2 or advancement to the dialysis stage. The result revealed that among all incident patients with CKD, 28.7{\%} and 30.3{\%} of the users and nonusers demonstrated CKD progression, respectively. The crude odds ratio (OR) of CKD progression was 0.93 [95{\%} confidence interval (CI) 0.78–1.10]. After adjustment for baseline characteristics, the adjusted OR was 0.80 (95{\%} CI 0.63–1.01). The sensitivity analysis results showed consistent OR for CKD progression, stratification by age, sex, Charlson score, and statins use within 1 year before index date. The effect of statins was significant in patients with CKD stage 3B-5 (OR 0.68, 95{\%} CI 0.48–0.95), but not statistically significant in those with CKD stage 1–3A (OR 0.97, 95{\%} CI 0.68–1.38). The effect of statins was significant in patients with proteinuria ≥1000 mg/day (OR 0.63, 95{\%} CI 0.43–0.92), but not statistically significant in those with proteinuria <1000 mg/day (OR 1.02, 95{\%} CI 0.74–1.41).",
author = "Hu, {Ping Jen} and Wu, {Mei Yi} and Lin, {Tsu Chen} and Chen, {Tzu Ting} and Wu, {Yun Chun} and Su, {Sui Lung} and Lu, {Kuo Cheng} and Chen, {Jin Shuen} and Sung, {Fung Chang} and Lee, {Chien Te} and Yu Yang and Hwang, {Shang Jyh} and Wang, {Ming Cheng} and Hsu, {Yung Ho} and Chiou, {Hung Yi} and Wong, {Chung Shun} and Lin, {Yuh Feng}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-34632-z",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Effect of Statins on Renal Function in Chronic Kidney Disease Patients

AU - Hu, Ping Jen

AU - Wu, Mei Yi

AU - Lin, Tsu Chen

AU - Chen, Tzu Ting

AU - Wu, Yun Chun

AU - Su, Sui Lung

AU - Lu, Kuo Cheng

AU - Chen, Jin Shuen

AU - Sung, Fung Chang

AU - Lee, Chien Te

AU - Yang, Yu

AU - Hwang, Shang Jyh

AU - Wang, Ming Cheng

AU - Hsu, Yung Ho

AU - Chiou, Hung Yi

AU - Wong, Chung Shun

AU - Lin, Yuh Feng

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Dyslipidemia is associated with glomerular injury. However, the effect of statins on chronic kidney disease (CKD) progression remains controversial. We aimed to investigate the efficacy of statins for renal protection in patients with CKD. The retrospective cohort study comprised 3441 patients diagnosed with CKD in multiple medical centers. We divided the patients into two cohorts based on statin prescription, and compared proportions and risks of CKD progression events between the two groups. CKD progression event was defined as an average annual decline of eGFR >5 mL/min/1.73 m2 or advancement to the dialysis stage. The result revealed that among all incident patients with CKD, 28.7% and 30.3% of the users and nonusers demonstrated CKD progression, respectively. The crude odds ratio (OR) of CKD progression was 0.93 [95% confidence interval (CI) 0.78–1.10]. After adjustment for baseline characteristics, the adjusted OR was 0.80 (95% CI 0.63–1.01). The sensitivity analysis results showed consistent OR for CKD progression, stratification by age, sex, Charlson score, and statins use within 1 year before index date. The effect of statins was significant in patients with CKD stage 3B-5 (OR 0.68, 95% CI 0.48–0.95), but not statistically significant in those with CKD stage 1–3A (OR 0.97, 95% CI 0.68–1.38). The effect of statins was significant in patients with proteinuria ≥1000 mg/day (OR 0.63, 95% CI 0.43–0.92), but not statistically significant in those with proteinuria <1000 mg/day (OR 1.02, 95% CI 0.74–1.41).

AB - Dyslipidemia is associated with glomerular injury. However, the effect of statins on chronic kidney disease (CKD) progression remains controversial. We aimed to investigate the efficacy of statins for renal protection in patients with CKD. The retrospective cohort study comprised 3441 patients diagnosed with CKD in multiple medical centers. We divided the patients into two cohorts based on statin prescription, and compared proportions and risks of CKD progression events between the two groups. CKD progression event was defined as an average annual decline of eGFR >5 mL/min/1.73 m2 or advancement to the dialysis stage. The result revealed that among all incident patients with CKD, 28.7% and 30.3% of the users and nonusers demonstrated CKD progression, respectively. The crude odds ratio (OR) of CKD progression was 0.93 [95% confidence interval (CI) 0.78–1.10]. After adjustment for baseline characteristics, the adjusted OR was 0.80 (95% CI 0.63–1.01). The sensitivity analysis results showed consistent OR for CKD progression, stratification by age, sex, Charlson score, and statins use within 1 year before index date. The effect of statins was significant in patients with CKD stage 3B-5 (OR 0.68, 95% CI 0.48–0.95), but not statistically significant in those with CKD stage 1–3A (OR 0.97, 95% CI 0.68–1.38). The effect of statins was significant in patients with proteinuria ≥1000 mg/day (OR 0.63, 95% CI 0.43–0.92), but not statistically significant in those with proteinuria <1000 mg/day (OR 1.02, 95% CI 0.74–1.41).

UR - http://www.scopus.com/inward/record.url?scp=85056027121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056027121&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-34632-z

DO - 10.1038/s41598-018-34632-z

M3 - Article

C2 - 30390007

AN - SCOPUS:85056027121

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 16276

ER -